TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Phil Nadeau maintained a Buy rating on Voyager Therapeutics (VYGR). The stock closed at $3.13. Nadeau, who covers the healthcare sector with a strong track record, is part of an analyst consensus that rates VYGR as a Strong Buy, with an average price target of $17.00.
TD Cowen analyst Phil Nadeau maintained a Buy rating on Voyager Therapeutics yesterday. The company’s shares closed yesterday at $3.13.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Nadeau covers the Healthcare sector, focusing on stocks such as Biogen, Voyager Therapeutics, and Enliven Therapeutics. According to TipRanks, Nadeau has an average return of 9.8% and a 48.84% success rate on recommended stocks.
Currently, the analyst consensus on Voyager Therapeutics is a Strong Buy with an average price target of $17.00.